Results 1 to 10 of about 7,915 (113)

GLP-1 receptor agonist-associated tumor adverse events: A real-world study from 2004 to 2021 based on FAERS

Frontiers in Pharmacology, 2022
Background: GLP-1 receptor agonists (GLP-1RA) have demonstrated cardiovascular benefits, but the relationship between GLP-1RA and tumors is controversial.
Subei Zhao, Yuhuan Lv, Linyu Xiang
exaly   +3 more sources

Cardiovascular outcomes of empagliflozin-GLP-1RA combination therapy in type 2 diabetes: EMPRISE study. [PDF]

Cardiovasc Diabetol
Background Evidence on the cardiovascular benefits of combining empagliflozin with glucagon-like peptide-1 receptor agonists (GLP-1RA) is limited, derived primarily from indirect comparisons or subgroup analyses of cardiovascular outcome trials.
Htoo PT, Cho H, Paik JM, Bykov K, Everett BM, Glynn RJ, Shay C, Schmedt N, Wexler DJ, Patorno E.   +9 more
europepmc   +2 more sources

Autoimmune Disease Risk With GLP-1RA, DPP-4i, and SGLT2i Treatment in Patients With Diabetes. [PDF]

ACR Open Rheumatol
Objective Dipeptidyl peptidase‐4 inhibitors (DPP‐4i), glucagon‐like peptide‐1 receptor agonists (GLP‐1RA), and sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) are widely used for type 2 diabetes, yet their comparative immunologic safety is uncertain ...
Mahajan A, Bates DW, Doria A, Foer D, LaChance AH, Sparks JA.   +5 more
europepmc   +2 more sources

Real-World Evidence of the GLP-1RA/SGLT2-i Therapy versus Standard Care: A Retrospective Cohort Study. [PDF]

Clin Med Insights Endocrinol Diabetes
Background Glucagon-like peptide-1 receptor agonists (GLP-1RA) and Sodium-glucose cotransporter-2 inhibitors (SGLT2-i) are effective antidiabetic therapies in patients with type 2 diabetes mellitus (T2DM).
Mahmoud NM, Hussein A, Mussa BM, Abusnana S.   +3 more
europepmc   +2 more sources

Disparities in SGLT2 Inhibitor or Glucagon-Like Peptide 1 Receptor Agonist Initiation Among Medicare-Insured Adults With CKD in the United StatesPlain-Language Summary

Kidney Medicine, 2023
Rationale & Objective: Information regarding disparities in initiating sodium/glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1RA) in patients with chronic kidney disease (CKD) is limited.
Julie Z. Zhao, Eric D. Weinhandl, Angeline M. Carlson, Wendy L. St. Peter   +3 more
doaj   +1 more source

Clinical and Patient-Related Variables Associated with Initiating GLP-1 Receptor Agonist Therapy in Type 2 Diabetes Patients in Primary Care in Germany. [PDF]

PLoS ONE, 2016
AIMS:To investigate real-world clinical and patient-related variables associated with initiating GLP-1 receptor agonist (GLP-1RA) treatment relative to initiation of other glucose-lowering therapies in type 2 diabetes (T2D) patients of primary care in ...
Qing Qiao, Susan Grandy, Josh Hiller, Karel Kostev   +3 more
doaj   +1 more source

Cardiovascular and Renal Effectiveness of GLP-1 Receptor Agonists vs. Other Glucose-Lowering Drugs in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Real-World Studies

Metabolites, 2022
Cardiovascular outcome trials (CVOT) showed that treatment with glucagon-like peptide-1 receptor agonists (GLP-1RA) is associated with significant cardiovascular benefits.
Irene Caruso, Angelo Cignarelli, Gian Pio Sorice, Annalisa Natalicchio, Sebastio Perrini, Luigi Laviola, Francesco Giorgino   +6 more
doaj   +1 more source

GLP-1RA and the possible skin aging. [PDF]

Endocrine
Paschou IA, Sali E, Paschou SA, Tsamis KI, Peppa M, Psaltopoulou T, Nicolaidou E, Stratigos AJ.   +7 more
europepmc   +2 more sources

Patient-perceived benefits and risks of off-label use of SGLT2 inhibitors and GLP-1 receptor agonists in type 1 diabetes: a structured qualitative assessment

Therapeutic Advances in Endocrinology and Metabolism, 2023
Background: Patients with type 1 diabetes mellitus (T1DM) may have suboptimal glucose control and are interested in the use of adjuvant therapies. Objectives: To determine, from the patients’ perspective, the reasons for initiation of glucagon-like ...
Khary Edwards, Aleksandra Uruska, Anna Duda-Sobczak, Dorota Zozulinska-Ziolkiewicz, Ildiko Lingvay   +4 more
doaj   +1 more source

The Efficacy of Treatment Intensification by Quadruple Oral Therapy Compared to GLP-1RA Therapy in Poorly Controlled Type 2 Diabetes Mellitus Patients: A Real-world Data Study [PDF]

Diabetes & Metabolism Journal, 2023
We compared the glycemic efficacy of treatment intensification between quadruple oral antidiabetic drug therapy and once-weekly glucagon-like peptide-1 receptor agonist (GLP-1RA)-based triple therapy in patients with poorly controlled type 2 diabetes ...
Minyoung Kim, Hosu Kim, Kyong Young Kim, Soo Kyoung Kim, Junghwa Jung, Jong Ryeal Hahm, Jaehoon Jung, Jong Ha Baek   +7 more
doaj   +1 more source